FDA Approves Optune Pax for Locally Advanced Pancreatic Cancer, First New Treatment in Nearly 30 Years
核心洞察
The FDA approved Optune Pax (搜索), a wearable device delivering tumor treating fields (搜索) (TTFields (搜索)), combined with chemotherapy for locally advanced pancreatic cancer (搜索) treatment.
The Phase 3 PANOVA-3 trial demonstrated a statistically significant 2-month improvement in median overall survival (16.2 vs 14.2 months) and extended pain-free survival.
This marks the first new treatment approved for locally advanced pancreatic cancer (搜索) in nearly three decades, offering a non-invasive biophysical approach.
The FDA has approved Optune Pax (搜索), a portable medical device that delivers tumor treating fields (搜索) (TTFields (搜索)), for the treatment of adult patients with locally advanced pancreatic cancer (搜索) when used concomitantly with gemcitabine and nab-paclitaxel. This approval represents the first new treatment option for locally advanced pancreatic cancer in nearly 30 years.
The approval was supported by results from the pivotal Phase 3 PANOVA-3 trial, which demonstrated a statistically significant improvement in overall survival. "Having treated many patients with pancreatic cancer (搜索), I know how difficult the diagnosis can be. The pancreatic cancer community deserves better therapeutic options," stated Marty Makary, MD, MPH, commissioner of the FDA.
Clinical Trial Results Demonstrate Survival Benefit
The international, randomized, open-label PANOVA-3 trial enrolled 571 patients who were randomly assigned 1:1 to receive either continuous TTFields (搜索) plus chemotherapy or chemotherapy alone. In the intention-to-treat population, patients treated with Optune Pax (搜索) concomitantly with gemcitabine and nab-paclitaxel achieved a median overall survival of 16.2 months (95% CI, 15.0-18.0) compared with 14.2 months (95% CI, 12.8-15.4) for those receiving chemotherapy alone (HR, 0.82; 95% CI, 0.68-0.99; P = .039).
The one-year survival rate was significantly higher in the experimental arm at 68.1% compared with 60.2% in the control arm (P = .029). In the modified per protocol population, which included patients who received at least 28 days of Optune Pax (搜索) therapy, the median overall survival improvement was even more pronounced at 18.3 months versus 15.1 months, representing a 3.2-month improvement (HR 0.77; 95% CI 0.62-0.97; P = 0.023).
Pain Management and Quality of Life Benefits
Beyond survival improvements, the trial demonstrated significant benefits in pain management, a critical concern for pancreatic cancer (搜索) patients. Patients treated with Optune Pax (搜索) experienced a median pain-free survival of 15.2 months (95% CI, 10.3-22.8) versus 9.1 months (95% CI, 7.4-12.7) in the chemotherapy-only group (HR, 0.74; 95% CI, 0.56-0.97; P = .027), representing a 6.1-month extension in time to pain progression.
Quality of life analyses using the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire showed that treatment with Optune Pax (搜索) resulted in longer deterioration-free survival in global health status, pain, pancreatic pain, and most digestive problems.
Novel Mechanism of Action
Optune Pax (搜索) delivers TTFields (搜索), alternating electric fields that target the electrical properties of cancer cells to disrupt processes critical for cancer cell division and survival, resulting in cell death without significantly affecting healthy cells. The device operates at a frequency of 150 kHz and is recommended for use at least 75% of the time, with array placement adapted to individual patients.
"Optune Pax (搜索) is a fundamentally different treatment, utilizing a biophysical approach that targets the unique electrical properties of cancer cells," said Frank Leonard, CEO of Novocure (搜索). "Systemic therapies have shown poor bioavailability in pancreatic tumors, limiting their effectiveness."
Safety Profile
The addition of TTFields (搜索) to gemcitabine and nab-paclitaxel did not exacerbate systemic toxicities. Any-grade adverse events occurred in 97.8% of the experimental arm and 98.9% of the control arm, with grade 3 or higher adverse events reported in 88.7% and 84.3%, respectively.
The most frequent grade 3 or higher toxicities were hematologic, including neutropenia (47.8% vs 47.6%), anemia (21.9% vs 22.3%), and leukopenia (17.2% vs 15.4%). Device-related adverse events were primarily dermatological, with skin reactions occurring in 76.3% of patients treated with TTFields (搜索). The majority of these skin events were mild to moderate (Grade 1-2), with only 21 patients (7.7%) experiencing Grade 3 or higher skin-related events. Discontinuation of the device due to toxicity occurred in 8.4% of patients.
Addressing Critical Unmet Need
Pancreatic cancer (搜索) remains one of the most lethal cancers and is the third most frequent cause of death from cancer in the United States. Approximately 67,000 patients are diagnosed with pancreatic cancer each year in the U.S., with a five-year relative survival rate of just 13%. While overall cancer incidence and death rates are remaining stable or declining, the incidence and death rates for pancreatic cancer are increasing.
"This approval provides a novel, non-invasive approach that can be integrated into patients' daily lives, expanding access to cancer care beyond traditional clinical settings," added Michelle Tarver, MD, PhD, director of the Center for Devices and Radiological Health of the FDA.
The device previously received breakthrough therapy designation in December 2024, and the developers submitted a premarket approval application in August 2025. Vincent Picozzi, M.D., MMM, a medical oncologist and investigator in the PANOVA-3 trial, noted that "with FDA approval, Optune Pax (搜索) has the potential to be practice changing for the treatment of patients with locally advanced pancreatic cancer (搜索)."